F-group (family)
5.1.3.3 Neur
Ligands and drugs
638
Member domains
605
with ligand contacts (≤ 4 Å)
94.8% of members
564
with DrugDomain annotations
88.4% of members
503
with a DrugBank compound
78.8% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5.1.3.3 belongs to X-group 5 beta-propeller-like, which binds 7.8 ligand superclasses per 20 proteins, broader than 52% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB00141 | NAG | N-Acetylglucosamine | 413 |
| DB02600 | G39 | Oseltamivir acid | 95 |
| DB00558 | ZMR | Zanamivir | 46 |
| DB03721 | SIA | N-acetyl-alpha-neuraminic acid | 33 |
| DB06614 | BCZ | Peramivir | 26 |
| DB03991 | DAN | 2-deoxy-2,3-dehydro-N-acetylneuraminic acid | 13 |
| DB12791 | LNV | Laninamivir | 13 |
| DB03740 | NDG | N-acetyl-alpha-D-glucosamine | 9 |
| DB11888 | LVO | Laninamivir octanoate | 6 |
| DB04473 | FUC | alpha-L-fucose | 5 |
| DB04211 | FSI | 5-(acetylamino)-3,5-dideoxy-3-fluoro-D-erythro-alpha-L-manno-non-2-ulopyranosonic acid | 3 |
| DB04265 | SLB | N-acetyl-beta-neuraminic acid | 3 |
| DB08570 | ST1 | 4-(ACETYLAMINO)-3-HYDROXY-5-NITROBENZOIC ACID | 3 |
| DB02268 | ST3 | 4-(Acetylamino)-3-Amino Benzoic Acid | 2 |
| DB02529 | G28 | (2R,4S,5R,6R)-5-Acetamido-4-amino-6-(diethylcarbamoyl)oxane-2-carboxylic acid | 2 |
| DB02829 | ST6 | 4-(Acetylamino)-3-[(Aminoacetyl)Amino]Benzoic Acid | 2 |
| DB03321 | 4AM | Des(carbamimidoyl) zanamivir | 2 |
| DB03503 | G20 | 4-Acetyl-4-guanidino-6-methyl(propyl)carboxamide-4,5-dihydro-2H-pyran-2-carboxylic acid | 2 |
| DB04565 | ST5 | 4-(Acetylamino)-3-[(Hydroxyacetyl)Amino]Benzoic Acid | 2 |
| DB08571 | ST2 | 4-(ACETYLAMINO)-5-AMINO-3-HYDROXYBENZOIC ACID | 2 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| CAmetal | CALCIUM ION | 532 |
| NAG | 2-acetamido-2-deoxy-beta-D-glucopyranose | 418 |
| G39 | (3R,4R,5S)-4-(acetylamino)-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylic acid | 95 |
| YT3metal | YTTRIUM (III) ION | 48 |
| ZMR | ZANAMIVIR | 45 |
| BCZ | 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID | 34 |
| SIA | N-acetyl-alpha-neuraminic acid | 28 |
| MAN | alpha-D-mannopyranose | 16 |
| BMA | beta-D-mannopyranose | 14 |
| DAN | 2-DEOXY-2,3-DEHYDRO-N-ACETYL-NEURAMINIC ACID | 13 |
| LNV | 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-D-glycero-D-galacto-non-2-enonic acid | 13 |
| NDG | 2-acetamido-2-deoxy-alpha-D-glucopyranose | 9 |
| LVO | 5-acetamido-2,6-anhydro-4-carbamimidamido-3,4,5-trideoxy-7-O-methyl-9-O-octanoyl-D-glycero-D-galacto-non-2-enonic acid | 6 |
| A1IVV | (3~{S},4~{R},5~{R},6~{R})-4,6-diacetamido-3-azanyl-5-pentan-3-yloxy-cyclohexene-1-carboxylic acid | 4 |
| A1IVW | (3~{S},4~{R},5~{R},6~{R})-4-acetamido-3-azanyl-5-pentan-3-yloxy-6-(pent-4-ynoylamino)cyclohexene-1-carboxylic acid | 4 |
| A1IVX | (3~{S},4~{R},5~{R},6~{R})-4-acetamido-3-azanyl-6-(butanoylamino)-5-pentan-3-yloxy-cyclohexene-1-carboxylic acid | 4 |
| CL | CHLORIDE ION | 4 |
| GJT | (3~{R},4~{R},5~{S})-4-acetamido-5-[4-(hydroxymethyl)-1,2,3-triazol-1-yl]-3-pentan-3-yloxy-cyclohexene-1-carboxylic acid | 4 |
| DPC | 5-ACETYLAMINO-4-AMINO-6-(PHENETHYL-PROPYL-CARBAMOYL)-5,6-DIHYDRO-4H-PYRAN-2-CARBOXYLIC ACID | 3 |
| EQP | (1R)-4-acetamido-1,5-anhydro-2,4-dideoxy-1-phosphono-D-glycero-D-galacto-octitol | 3 |